Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan‐Khan(Mayo Clinic in Florida), Paula Cramer(University of Cologne), Fatih Demırkan(Dokuz Eylül University), Graeme Fraser(Juravinski Cancer Centre), Rodrigo Santucci Silva, Sebastian Grosicki(Medical University of Silesia), Aleksander Pristupa, Ann Janssens(Universitair Ziekenhuis Leuven), Jiřı́ Mayer(University Hospital Brno), Nancy L. Bartlett(Washington University in St. Louis), Marie‐Sarah Dilhuydy(Hôpital Cardiologique du Haut-Lévêque), Halyna Pylypenko, Javier Loscertales(Hospital Universitario de La Princesa), Abraham Avigdor(Sheba Medical Center), Simon Rule(Derriford Hospital), Diego Villa(BC Cancer Agency), Olga Samoilova(Nizhny Novgorod Regional Clinical Hospital named after Semashko), Panagiots Panagiotidis(National and Kapodistrian University of Athens), André Goy(Hackensack University Medical Center), Anthony R. Mato(University of Pennsylvania), Miguel Arturo Pavlovsky(Fundación para la Investigación, Docencia y Prevención del Cáncer), Claes Karlsson(Karolinska University Hospital), Michelle Mahler(Janssen (United States)), Mariya Salman(Janssen (United States)), Steven Sun(Janssen (United States)), Charles E. Phelps(Janssen (United States)), Sriram Balasubramanian(Janssen (United States)), Angela Howes(Janssen (United Kingdom)), Michael Hallek(University of Cologne)
Cited by 409
Abstract
Related Papers
No related papers found
Powered by citation graph analysis